The patent protections for Ozempic, a popular diabetes medication, are set to expire in several countries, including India and China. New York Times posted on X, highlighting that this development could pave the way for more affordable generic versions of the drug. As patents lapse, pharmaceutical companies in these regions may begin producing and distributing generic alternatives, potentially reducing costs for consumers and increasing accessibility to the medication. The expiration of these patents marks a significant shift in the pharmaceutical landscape, as it may lead to increased competition and innovation in diabetes treatment options. This change is expected to impact the global market, influencing pricing strategies and availability of diabetes medications.